ZIM Laboratories board meet May 19 for FY26 results

Overview of the May 19 board meeting

ZIM Laboratories Limited (NSE: ZIMLAB) has informed stock exchanges that its Board of Directors will meet on Tuesday, May 19, 2026. The company said the meeting is scheduled to consider and approve its audited financial results for the quarter and full year ended March 31, 2026. The results are to be reviewed on both a standalone and consolidated basis. The disclosure was filed on May 12, 2026. The update is relevant for investors tracking the company’s FY26 close and the audited performance print.

What the company disclosed to exchanges

The intimation was made under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Such disclosures typically set expectations on when audited numbers will be reviewed at the board level and subsequently released to the market. ZIM Laboratories’ filing indicates that the May 19 meeting will cover the audited results for the quarter ended March 31, 2026 (Q4 FY26) as well as the full year ended March 31, 2026 (FY26). The company explicitly referenced both standalone and consolidated financial statements in the agenda.

Agenda: audited Q4 and full-year results

According to the exchange intimation, the board meeting has been convened to “consider and approve” the audited financial results for the relevant periods. Because the results are audited, the announcement will also serve as the final set of numbers for FY26, as opposed to limited review financials released during the year. Investors typically focus on year-end audited accounts for clarity on annual profitability, working capital movements, and any audit-related notes and qualifications, if any. The company’s communication, however, is limited to the meeting schedule and the purpose of approving audited results.

Key dates that matter for shareholders

The dates provided in the filing establish a clear sequence for the results process. The intimation date is May 12, 2026, while the board meeting is set for May 19, 2026. In addition, the trading window closure spans a defined period connected to the results event. For shareholders, these dates help plan around information flow, especially for those who track regulated trading window norms applicable to designated persons.

Trading window closure: compliance with insider trading norms

ZIM Laboratories also communicated a trading window closure in line with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company’s internal code of conduct for insiders. The company said the trading window is closed from April 1, 2026 to May 21, 2026, inclusive of both days. During this period, designated persons are restricted from dealing in the company’s securities. The company indicated the window will reopen after May 21, 2026, following the conclusion of the board meeting and dissemination of financial results.

Sign-off and compliance detail in the filing

The intimation was signed by Piyush Nikhade, Company Secretary and Compliance Officer (Membership No. A38972), on behalf of ZIM Laboratories Limited. Exchange filings signed by compliance officers are a standard part of listed-company disclosure and accountability. The company’s statement ties the trading window closure directly to the scheduled board meeting and results dissemination process.

Recent financial snapshot: Q3 FY26 and nine-month performance

While the May 19 meeting relates to audited Q4 and full-year results, the article text also includes the company’s unaudited financial performance for the quarter and nine months ended December 31, 2025 (Q3 FY26 and 9M FY26). For the quarter ended December 31, 2025, the company reported consolidated revenue from operations of ₹108.6593 crore, compared with ₹96.3303 crore in the corresponding period last year. Consolidated profit after tax for the quarter was ₹4.3976 crore, versus ₹4.0008 crore in the comparable quarter of the previous year. For the nine months ended December 31, 2025, consolidated revenue from operations was ₹269.1267 crore and profit after tax was ₹2.0981 crore.

The standalone numbers for the quarter ended December 31, 2025 were also included in the text. Standalone revenue from operations was ₹107.8058 crore and standalone profit after tax was ₹4.2590 crore. The limited review reports from Deloitte Haskins & Sells LLP, the statutory auditors, were enclosed with those unaudited results. The board meeting for those results commenced at 4:00 p.m. IST and concluded at 6:45 p.m. IST.

How this fits into the company’s reporting cadence

The article text references multiple prior board meeting intimations and outcomes related to quarterly and audited results across 2025 and early 2026. For example, ZIM Laboratories held a board meeting on February 11, 2026 to approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. It also references board meeting communications for November 12, 2025 (unaudited results for the quarter and half-year ended September 30, 2025) and August 7, 2025 (unaudited results for the quarter ended June 30, 2025). The dataset also includes a May 20, 2025 meeting for audited results for the quarter and year ended March 31, 2025.

Dividend-related mentions: what is and is not confirmed

The provided text includes a line stating the board will consider a final dividend recommendation and separately states that ZIM Laboratories is “expected to consider” ₹2 per share at the Q4 FY26 board meeting. However, the detailed exchange intimation section included in the same text only specifies approval of audited financial results as the purpose. Based on the material provided, the dividend point appears as an expectation in secondary commentary, and not as a confirmed agenda item in the board meeting details table.

Market impact: why the board meeting notice matters

A scheduled board meeting for audited results is a key trigger for near-term information updates in listed stocks. It defines the timeline for audited financial disclosure and the period during which insider trading restrictions are applied to designated persons. For investors, the May 19 date serves as a marker for when audited FY26 numbers will be considered for approval and then released. The trading window closure period, as communicated, also signals that the company is operating within a defined compliance framework around unpublished price sensitive information.

Key facts at a glance

Financial snapshot mentioned in the text (converted to ₹ crore)

Conclusion

ZIM Laboratories has set May 19, 2026 as the date for its board meeting to consider and approve audited standalone and consolidated results for Q4 FY26 and the full year ended March 31, 2026. The company has also kept the trading window closed from April 1 to May 21, 2026, in line with insider trading compliance requirements. Investors will watch for the audited numbers after the board’s review and the subsequent dissemination of results to the exchanges.